STUDresearch · Peptide
BPC-157
Also known as
Body Protection Compound-157 · BPC 157 · BPC157 · PL 14736 · PL14736 · PL-10 (oral Bepecin trial code discussions) · Bepecin (research designation) · Stable gastric pentadecapeptide BPC 157 · Pentadeca arginate / PDA (arginate salt marketing name) · Arg-BPC / BPC-157 arginate (oral-stability form talk)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Mixed
SubQ / IM
Healing & repair
Mixed — near-injury pin for a limb, belly for whole-body/gut talk. People argue both.
What people say
BPC-157 is a synthetic 15-amino-acid peptide discussed for tendon and injury recovery, stiffness and gut symptoms.Often paired with TB-500 or rehab, making individual effects hard to separate.
Doses people talk about
Daily totals are not per-injection amounts. Higher reports do not establish a safe ceiling; oral and nasal discussions remain in the full notes.
How it may feel
Reports include little immediate sensation, site sting, headache, nausea, fatigue or feeling detached. Stiffness and gut changes, when reported, unfold over days or weeks.
Subcutaneous discussion range250–500 mcg total per day
Injury reports describe once-daily or divided totals, not human dose-finding results.
Higher reports750–1,000 mcg total per day
Some tendon and post-operative logs; not a recommended next step.
Half-life & effect duration
- Half-life in the body
- IV · dogsAbout 5.3 minutes
- IV · ratsAbout 15.2 minutes
- Into muscle · ratsAbout 8–30 minutes
- Oral / under-the-skin injectionNo settled estimate
- Felt duration people report
- Stomach discomfort30–60 minutes in one account
- Shoulder changesReported across a 16-day course
Cycles people discuss
In the existing notes, acute-injury discussions describe 2–4 weeks, while chronic-tendon accounts describe 4–8 weeks or longer. Breaks vary; these are not validated cycle lengths.
Timing
Daily routines, sometimes split morning and evening, appear alongside post-training and bedtime patterns. Oral food-timing practices are not standardized.
Stacks
Wolverine stack (core dual): BPC-157 + TB-500 — the most named injury stack. Typical discussed pattern: BPC ~250–500 mcg daily subq; TB-500 ~2–2.5 mg twice weekly load then ~2–2.5 mg once weekly maintain (TB weekly totals often ~4–10 mg load phase).
Access talk
What they reviewed: Ulcerative colitis — not the tendon/injury use most forums buy it for.
Labs people mention
No BPC lab: Community 2026 posts say it does not reliably move testosterone, glucose, or a standard hormone panel.
Watch for
Systemic nonspecifics: Existing logs include headache, fatigue, dizziness, nausea and flushing; their frequency is not established. One 16-day log also described rapid workout heart-rate rise, palpitations and suspected higher blood pressure. Illness, training and unverified product identity confound attribution.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human oral or subcutaneous half-life is not established by the reviewed evidence.
Animal IV/IM parent half-lives were under 30 minutes; that is not a human duration estimate.
Animal clearance, radiolabeled metabolites and human pharmacokinetics are different endpoints. The FDA assessment separately identifies unknown PK for the nominated human routes.
- He et al.: BPC-157 pharmacokinetics in rats and dogs (opens in a new tab)Abstract; Results 2.1 and 2.2; tables 1–6; DiscussionIV/IM animal experiments, not human oral or subcutaneous PK. Total radiolabel includes metabolites and must not be substituted for parent-peptide half-life.
- FDA July 2026 BPC-157 assessment (opens in a new tab)Slide 44, Pharmacokinetics; separate Nonclinical and Clinical subsectionsAssessment at that date; unknown nominated human-route PK is not proof that no future study can establish it.
Felt duration people report
No dependable per-dose duration emerges from these accounts. One describes stomach discomfort lasting 30–60 minutes; another describes shoulder changes across a 16-day course.
A brief symptom and a change across repeated use are different clocks—not one half-life.
These accounts do not prove injury healing or drug causation. Product identity, illness, training changes and other factors were uncontrolled.
- Stomach ache from BPC-157? (opens in a new tab)Opening report; author's later comment describing IM and SC useOne uncontrolled account of an adverse sensation; neither purity nor a causal link was verified.
- BPC-157 Log (Completed) (opens in a new tab)xovyz opening summary and numbered Side effects 1–5:16-day SC log; shoulder changes, headache/nausea, palpitations, derealization and illness confounding.Single uncontrolled log; subjective shoulder improvement is not measured healing, and the course length is not an effect-duration measurement.
What people say
- Tendon & ligament: Most common win stories — Achilles, elbow (golfer’s/tennis), rotator cuff, knee soft tissue, plantar fascia — users report multi-week drop in daily pain/irritation noise. forumanecdote
- Muscle soft-tissue: Strains, tweaks, and overuse “pulls” are frequent success anecdotes, often confounded by rest and PT. forum
- Joint comfort / training load: Easier stairs, less warm-up pain, ability to keep training at reduced volume claimed in 2–4 weeks. forum
- Vs TB-500 mental model: Community frames BPC as more “targeted repair / local-first,” TB-500 as more systemic mobility/whole-body recovery — not a head-to-head trial result. forum
- Stack halo: “Wolverine,” “GLOW,” and “KLOW” blends make single-agent credit unreliable; PT, sleep, and deload often co-own outcomes. forum
- What people do not reliably claim: Instant day-1 pain wipe for complete tears, guaranteed surgery avoidance, or consistent results across gray-market product quality. forum
- Women vs men: No solid sex-split trial. Some 2025–26 blogs tell smaller/lighter users (often women) to start ~200–300 mcg; most injury threads still compare the same 250–500 mcg chart. forum
- Fertility / endo marketing (minority): A loud minority on X and clinic blogs talks lining, endometriosis pain, or “surprise pregnancy.” No human fertility RCT; pregnancy and breastfeeding are still treated as avoid. forumanecdote
- Gut claims: Oral (and some injectable) talk of less IBS-like discomfort, NSAID-context gut irritation, “leaky gut” forum framing, and general GI lining support — closest area to historical clinical development interest. forumtrial
- Wound / fistula animal models: Rodent literature often cited for accelerated healing metrics across GI and soft-tissue injury models. animal
- Human MSK honesty: One frequently cited retrospective: 7 of 12 patients with chronic knee pain reported >6 months relief after a single intra-articular BPC-157 injection (reported as ~2 cc of 2000 mcg/mL solution in secondary sources) — small, uncontrolled, not a soft-tissue RCT. trial
Doses people talk about
- Default chart (still dominant): ~250–500 mcg/day SC once daily or split AM/PM remains the default injury-thread range across ExcelMale-style boards and peptide blogs. forum
- Injectable daily (most common band): ~250–500 mcg/day subcutaneous is the default “chart” range across injury threads and peptide blogs. forum
- First-cycle conservative talk: ~250 mcg once daily often recommended by experienced posters before jumping to 500 mcg. forum
- Split dosing: 250 mcg AM + 250 mcg PM (or 500 mcg total split) is very common when people want “steadier coverage” given short half-life lore. forum
- Upper community logs: ~750–1,000 mcg/day total (often split 2×) appears in stubborn Achilles/tendon and post-op logs; not a validated ceiling. forumanecdote
- Per-injection range language: Clinic-style writeups often say ~200–500 mcg once or twice daily for ~2–6 weeks (acute) or longer for chronic talk. forum
- Body-weight forum math: Some guides cite ~2.5 mcg/kg/day or animal-style ~10 mcg/kg rodent references; simple kg scaling from rats is widely warned as wrong without BSA conversion, and most bro charts still use flat 250–500 mcg regardless of weight. forumanimal
- Localized subq: Near (not deep into joint capsule or tendon substance) the complaint site for accessible limb injuries — shoulder, elbow, Achilles, knee soft tissue. forum
- Systemic subq: Lower abdomen / love-handle rotation when injury is deep (hip, spine talk) or when users believe “it’s systemic anyway.” forum
- Oral capsules / liquids: Multi-hundred mcg to low-mg daily discussed for gut goals; soft-tissue users often told injectables are preferred for tendons. Typical oral charts echo ~200–500 mcg 1–2×/day for longer (e.g. 6–8 week) gut-leaning blocks. forum
- Acetate vs arginate (oral debate): Injectable form usually acetate lyophilized; oral marketing pushes arginate / “pentadeca arginate (PDA)” as far more gastric-stable than acetate. Vendor claims of huge oral stability gaps circulate widely; independent peer-reviewed head-to-head human PK is thin — treat as community/vendor narrative. forumtrial
- Separate vs pre-mix: Solo BPC vials keep mcg math clear; Wolverine/GLOW pre-mixes force you to accept vendor ratios. forum
- Purity uncertainty: Gray-market labeled mcg ≠ delivered peptide; underdosing, overdosing, and wrong sequence are structural risks. forum
- Higher “stubborn injury” camp: Some logs push ~500–1000 mcg/day total for chronic tendinopathy talk — more cost and ISR burden, not more proof. forum
- Oral camp: Oral BPC/arginate products get gut-healing talk; many still say injectables dominate soft-tissue threads. forum
- Nasal camp: Pre-made or home sprays are discussed around ~250–500 mcg per spray, sometimes higher “to make up for poor absorption.” Same mcg is not treated as the same as SubQ. forum
- U-100 unit fight: The chart people screenshot is 5 mg vial + 2 mL BAC → 250 mcg ≈ 10 units on a U-100 (100 units = 1 mL). 1 mL water makes that ~5 units; 2.5 mL makes ~12.5. Units mean nothing until you know the water. forum
- Animal reference (not a human protocol): Rodent injury models commonly discuss ~10 mcg/kg (range talk ~1–50 mcg/kg depending on model); human equivalent estimates via BSA are much lower than many forum doses — the gap is why community dosing is experience-driven, not pure HED. animaltrial
- Intra-articular: Appears in small clinical retrospective series (knee), not standard self-experimenter practice; technique and sterility risk differ from subq. trial
- Framing: Community- and clinic-discussed research ranges only — not medical advice, not prescriptions, not verified product content. forum
How it may feel
- Days 1–3: Most injury users report little systemic “feel”; injection-site sting or mild redness possible. Oral gut users sometimes claim earlier GI shifts. forum
- Days 1–7: Soft-tissue logs often still flat; some note slightly less morning stiffness or movement “complaint noise.” A minority report a transient “buzz,” fuzzy head, or fatigue after shots. forumanecdote
- Weeks 1–2: Common first believable checkpoint for joint/tendon irritation easing under concurrent rehab. forum
- Weeks 3–4: Standard community decision point — progress, hold course, change route (local vs systemic vs oral), or reassess diagnosis/load. forum
- Weeks 4–8: Typical full acute soft-tissue block length; stubborn tendons may still be incomplete. forum
- Months 2–3: Some claim consolidated gains and taper; others re-run or add TB-500 if plateaued. forum
- If no change by ~4 weeks: Forums generally push diagnosis, load management, sleep, and product authenticity before auto-escalating mcg. forum
- Post-cycle: Minor issues sometimes “stick”; hard structural problems often return when training load returns. anecdote
- No “on” feeling: Not a stimulant or pump peptide. First days are usually nothing except pin sting; the week 2–4 “less noisy tendon or gut” window is what logs actually compare. forum
- Bloodwork people mention: 2026 Wolverine-lab posts often name hs-CRP / ESR and a basic CMP/liver panel. Careful threads also say BPC is mostly invisible on hormones and standard bloodwork — labs are a baseline, not a “BPC marker.” forum
Around the dose
- Clock: Daily, often split AM/PM in injury threads. Time of day is less argued than “every day while the complaint is loud.” forum
- Training: Post-session or away from the heavy set. Not a pre-workout. Load management still gets credited when a log looks good. forum
- Site habit: Near-injury SubQ for a limb; abdomen for gut/systemic talk. Don’t spend an hour hunting a “perfect spot.” forum
- Habits: PT, sleep, and not re-aggravating the tendon are the pairing. BPC without those is a frequent null log. forum
- After: Keep moving in a tolerable range. Complete rest plus BPC is mixed in tendon threads. forum
- Oral gut days: Oral/arginate talk is gut-first — people still treat food, NSAIDs, and sleep as the other half. forum
- Belly vs site (still loud in 2026): One camp: SubQ anywhere is systemic, so abdomen is fine and “near the tendon” is folklore. Other camp: only near-site pins moved their Achilles/reattachment log. No RCT winner. forum
Cycles people discuss
- Acute soft-tissue blocks: ~2–4 weeks common; many extend to 4–6 weeks if still improving. forum
- Stubborn tendon / chronic: ~4–8+ weeks of daily (or 2× daily) injectable talk; still anecdotal. forum
- Clinic-style Wolverine pairing: BPC daily for the block while TB-500 loads 2×/week then maintains — total stack often ~4–8 weeks, sometimes up to ~12 in chronic talk. forum
- Gut oral blocks: Often described as similar or slightly longer (e.g. 6–8 weeks) with reassessment. forum
- Continuous vs pulsed: Daily continuous for a block is default; some pulse around training camps or flare-ups only. forum
- Time off: Inconsistent — some mirror “equal time off,” some take ~2–4 weeks off after 6–8 on, others stop when symptoms resolve and restart next injury season. No solid long-term safety database. forum
- 5 on / 2 off: Occasional clinic or user protocols (e.g. weekdays on) appear in logs; less universal than straight daily. forumanecdote
- Re-runs: Very common across later injury seasons; product source and concurrent rehab vary wildly. forum
- Injury block: Commonly ~4–6 weeks on for acute tweaks; chronic complaints sometimes ~8–12 weeks then off — reassess, don’t “forever pin.” forum
- 5-on-2-off clinic lore: Some med-spa writeups use weekday pins / weekend off for convenience — culture, not a pivotal trial design. forum
Timing
- Daily / twice-daily discussion: Community accounts favor daily or twice-daily injectables rather than the weekly-style TB-500 pattern. Short-plasma-duration explanations are lore; verified human SC kinetics do not establish those schedules. forum
- Tissue vs blood: Users and some preclinical writeups separate short plasma residence from longer local wound/exudate activity and multi-day pharmacodynamic “repair window” claims. animalanecdote
- Downstream repair narrative: “It keeps working after levels fall” is common lore — used to justify not chasing continuous blood levels. anecdote
- Injection timing prefs: Post-training, pre-sleep, or “whenever convenient” — no controlled comparison; consistency beats folklore timing. forum
- Oral timing: Sometimes away from large meals; practices not standardized. forum
- Insulin / food interference lore: Some forums claim large carb/insulin spikes near dosing reduce effect — low-evidence bro rule, not a trial finding. forum
- Animal parent-peptide PK: Dog IV mean half-life was 5.3 minutes and rat IV mean was 15.2 minutes; rat IM means were 7.87–29.7 minutes. The older ~8–30-minute shorthand describes animal results, not human SC or oral clearance. animal
- Human PK: Early Bepecin/PL oral Phase work and the NCT02637284 registration remain historical study leads, not published human clearance curves. FDA’s July 2026 assessment identified unknown PK for nominated oral, SC, nasal and transdermal routes. trial
More on what it is
- What most people mean: Injury/tendon “heal peptide” people start with — not a GH secretagogue, not a fat-loss shot. forum
- Why people search: Highest-volume research peptide for injury, tendon/ligament, gut, and “Wolverine” stack threads across Reddit, Discord, clinics, and bodybuilding forums. forum
- Mechanism talk (forum-simplified): Angiogenesis / VEGF–VEGFR2 signaling, nitric-oxide pathway modulation, growth-factor and fibroblast-friendly repair narratives, and gastric-juice stability lore that underpins oral interest. forumanimal
- Research lens: Dose charts and “healed in 2 weeks” posts are discussion artifacts until matched to a named study, verified product, and controlled rehab. forum
- Bodyweight dose talk: Some 2025–26 coaches/blogs push ~5–10 mcg/kg SC (e.g. ~400–800 mcg at 80 kg) instead of flat 250–500 mcg charts — both camps coexist; neither is a medical label. forum
- Local vs belly: Endless forum debate: pin near the tweak vs systemic abdomen SC. No clean RCT winner; both are common. forum
- 2026 compounding-vote headline: July 23, 2026 FDA PCAC voted 8–6 (1 abstention) to recommend BPC-157 free base and acetate for the 503A bulks list. The use they actually reviewed was ulcerative colitis, not sports tendons. trialforum
- Not FDA-approved: That vote is an advisory compounding-list recommendation. It is not a drug approval, not a final 503A listing, and not a green light that the peptide “works.” Rulemaking still had to happen. trialforum
- Three events people smash together: Coming off Category 2 (Apr 2026), the PCAC recommendation, and actual 503A placement after notice-and-comment. Forums treat those as one “FDA approved BPC” headline. They are not. forumtrial
- Nasal size talk (2026): Community nasal charts put BPC around ~1,400 Da (often ~1,419 Da), over the ~1,000 Da “absorbs well” cutoff, so people call nasal borderline-poor vs a pin. No published human nasal PK. Some blog tables float ~10–15% vs inject — that is chart talk, not a named human study. forumtrial
- What it is: Synthetic 15-amino-acid (pentadecapeptide) sequence related to a gastric body-protection protein fragment; research peptide, not an approved healing drug. trial
- Also called: Body Protection Compound-157, PL 14736, Bepecin in development/trial talk. trial
- Gastric stability claim: Unlike many growth-factor peptides, BPC-157 is repeatedly described as stable in human gastric juice for many hours (literature often cites >24 h intact) — the core rationale for oral/gut use discussions. trialanimal
- Evidence shape: Dense rodent tendon, muscle, fistula, and GI injury literature (Sikiric et al. body of work heavily cited); few large modern human RCTs for sports soft-tissue healing. animaltrial
- Human signals named in reviews: Early IBD/Bepecin oral development work; a small retrospective knee intra-articular series (7/12 chronic knee pain >6 months relief after one IA injection reported); Phase I PK/safety registrations that did not yield an approved indication. trial
- What it is not: Not a steroid, not a GH secretagogue, not FDA-approved for injury or gut disease, not full gastric juice protein — a short synthetic peptide. trial
Stacks
- Wolverine stack (core dual): BPC-157 + TB-500 — the most named injury stack. Typical discussed pattern: BPC ~250–500 mcg daily subq; TB-500 ~2–2.5 mg twice weekly load then ~2–2.5 mg once weekly maintain (TB weekly totals often ~4–10 mg load phase). forum
- Wolverine pre-mix ratios: Vendor/clinic blends vary — examples in market talk include ~5 mg BPC + ~10 mg TB per vial, or equal ~10 mg/10 mg per vial; always read the label. forum
- Separate vials preferred by many: Keeps BPC daily mcg and TB multi-mg weekly schedules independent and avoids forced ratio. forum
- KLOW stack: GLOW foundation + KPV — often discussed as ~50 mg GHK-Cu + ~10 mg KPV + ~10 mg BPC-157 + ~10 mg TB-500 (~80 mg total vial talk). Extra gut/inflammation narrative. forum
- Gut-leaning combos: Oral BPC ± KPV, sometimes other GI peptides; injectable BPC still used by some for gut. forum
- GH-axis adjacency: Stacked lifestyle-wise with CJC-1295/Ipamorelin, sermorelin, or MK-677 for sleep/recovery — highly confounded outcomes. forum
- PT / load management: Deload, physical therapy, sleep, and progressive loading share credit in almost every honest log. forum
- Not a steroid cycle add-on by default: Some PED users add it during or after heavy training blocks; that does not make it anabolic in the AAS sense. forum
- Wolverine: BPC + TB-500 is still the default soft-tissue duo on X/Reddit injury threads. forum
- GLOW / KLOW: Pre-blends adding GHK-Cu (± KPV) are loud in 2025–26 “heal and look better” content. forum
- GLOW stack: BPC-157 + TB-500 + GHK-Cu. Common research-chem pre-blend talk: ~50 mg GHK-Cu + ~10 mg TB-500 + ~10 mg BPC-157 per vial (5:1:1 GHK-dominant). Skin/collagen + recovery framing. forum
Access talk
- What they reviewed: Ulcerative colitis — not the tendon/injury use most forums buy it for. trialforum
- Not a final rule: Advisory recommendation only. Notice-and-comment rulemaking still required; as of late 2026 it was not “on the list.” trialforum
- April 2026 Category 2 off: Coming off the do-not-compound bucket is not Category 1, not 503A placement, and not FDA drug approval. trialforum
- Three buy identities: Prescription compounding (if/when legal), clinic “peptide therapy,” and RUO / gray-market research vials. People mix those labels constantly. forum
- RUO still the loud path: Research-use-only vendors did not become pharmacies because a committee voted. forum
- July 23, 2026 PCAC: 8–6, one abstention, for BPC-157 free base and acetate on the 503A bulks list. FDA staff had recommended against. trial
Labs people mention
- No BPC lab: Community 2026 posts say it does not reliably move testosterone, glucose, or a standard hormone panel. forum
- What people still draw: hs-CRP / ESR if the story is inflammation, plus CMP/liver as a baseline before a pin block. forum
- Don’t chase a number: A quieter tendon is the log people actually compare, not a lab printout. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
- Unit-math fight, not a recipe: People screenshot “10 units = 250 mcg” then argue because someone used 1 mL instead of 2 mL. Same labeled vial, different water, different ticks. forum
Watch for
- Injection site: Redness, stinging, itching, bruising, or lumps — worse with poor technique, reused needles, or same-site hammering. forum
- Systemic nonspecifics: Existing logs include headache, fatigue, dizziness, nausea and flushing; their frequency is not established. One 16-day log also described rapid workout heart-rate rise, palpitations and suspected higher blood pressure. Illness, training and unverified product identity confound attribution. forumanecdote
- Mood / anhedonia reports: A subset of multi-week users report anxiety, flat affect, reduced pleasure, or “emotional numbness”; causality vs purity/confounders is unproven, but the thread volume is real enough to list. forumanecdote
- Appetite / sleep: Occasional appetite shift or insomnia notes — not a stable consensus effect. anecdote
- Cancer / angiogenesis caution: Pro-angiogenic and growth-pathway talk (VEGF/VEGFR2, etc. in animal literature) fuels theoretical concern about active or occult malignancy; no demonstrated human cancer-causation signal, but absence of long-term controlled data is the point of the caution. forumanimaltrial
- Source quality: Gray-market contamination, wrong peptide, under/over-filled vials, and endotoxin risk are structural — side effects may be the vial, not BPC. forum
- Drug interactions: No systematic human interaction database behind forum charts; stacking with other peptides or meds is uncontrolled experiment. forum
- Pregnancy / unknown long-term: No adequate human reproductive or multi-year safety data — community consensus is avoid. forumtrial
- Infection risk: Any injectable multi-use vial can introduce skin flora if technique fails. forum
- Usually mild logs: Most community AEs are pin-site redness/itch; systemic “bad” reports exist but are less consistent than GLP-1 GI stories. forum
- Regulatory noise: Compounding/FDA status chatter shifts — always separate “what forums run” from “what a pharmacy can legally compound where you live.” forum
- “FDA approved” mix-up: PCAC-yes headlines are not purity, legality, or efficacy stamps. RUO vials, clinic compounds, and a future 503A listing are three different identities. forum
- Nasal drip / taste: Spray users report sneeze, drip, or tasting it in the throat — on top of the absorption argument. forumanecdote
- Author literature counter-narrative: Some BPC-focused reviews argue the angiogenesis profile is context-modulated (not simple “feeds tumors”) and cite anti-pathological angiogenesis patterns in certain models — still not a green light for oncology patients. animaltrial
- WADA / sport: Listed as prohibited under WADA S0 Non-Approved Substances — banned at all times for tested athletes. Also flagged in military/DoD supplement prohibition contexts. trial
- Legal / regulatory: Research-only / unapproved drug framing in the US and many jurisdictions; not a dietary supplement ingredient. Rules vary by country. trial
- Never risk-free framing: Popularity and “well tolerated in rats” language do not equal established human safety for chronic self-use. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.